Other metabolic diseases

show blocks helper

Sort by Default

Display 15 Products per page

Disease Analysis: Osteoporosis
Read More
Osteoporosis is the most common metabolic bone disease, and is characterized by compromised bone strength which predisposes individuals to an increased risk of fracture. Bone strength itself is not directly measurable, but can be inferred from bone mass and quality, with bone mass being most commonly approximated by assessing bone mineral density (BMD). A person with a BMD measurement that falls within one standard deviation (SD) of the healthy reference (30-year-old male or female is considered to have healthy bone mass and structure (T-score >-1).
December 10, 2020
Find out more
Market Spotlight: Duchenne Muscular Dystrophy (DMD)

$1,318.00

This Market Spotlight report covers the Duchenne muscular dystrophy market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 12, 2020
Find out more
Market Spotlight: Obesity

$1,318.00

This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 12, 2020
Find out more
Disease Analysis: Dyslipidemia
Read More
Dyslipidemia refers to any increase or decrease in lipid levels from defined normal parameters, with physicians particularly focusing on the treatment of elevated LDL-C due to the well-established link between excessively elevated LDL-C and atherosclerosis. As such, LDL-C is a major modifiable risk factor for cardiovascular disease, one of the world’s leading causes of morbidity and mortality, though differences in LDL particle morphology can also play a role
November 12, 2020
Find out more
Market Spotlight: Renal Disease

$1,318.00

This Market Spotlight report covers the renal disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 12, 2020
Find out more
Market Spotlight: Lysosomal Storage Disorders

$1,318.00

This Market Spotlight report covers the Lysosomal Storage Disorders market, comprising epidemiology, key marketed and pipeline drugs, recent events and analyst opinion, key regulatory events, licensing and asset deals, and probability of success.
October 19, 2020
Find out more
Non-alcoholic steatohepatitis (NASH) Market and Forecast Analysis to 2038
Read More
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of patients who have fatty liver in the absence of significant alcohol consumption. NAFLD patients are often segmented into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) patients.
October 14, 2020
Find out more
Market Spotlight: Amyloidosis

$1,318.00

This Market Spotlight report covers the amyloidosis market, comprising key marketed and pipeline drugs, key upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
October 8, 2020
Find out more
Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

$599.00

Key topics discussed in this specialist interview with a US-based key opinion leader (KOL) include the diagnostic landscape in NASH and future market trends, with a focus on GLP-1 agonists, FGF 19/21 analogs, and FXR agonists.
August 28, 2020
Find out more
Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

$599.00

This reimbursement interview with a US key opinion leader (KOL) provides insight into pricing strategies, pricing barriers, and potential reimbursement criteria for non-alcoholic steatohepatitis therapies.
May 20, 2019
Find out more
Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

$599.00

This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.
May 20, 2019
Find out more
Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

$599.00

This interview with a US key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies, diagnostic tools, and future treatment rates for the different fibrosis stages of NASH. Key pipeline assets highlighted include Ocaliva, elafibranor, cenicriviroc, and firsocostat.
May 20, 2019
Find out more
Dyslipidemia Disease Analysis and Market and Forecast Analysis 2024
Read More
Dyslipidemia refers to any increase or decrease in lipid levels from defined normal parameters, with physicians particularly focusing on the treatment of elevated LDL-C due to the well-established link between excessively elevated LDL-C and atherosclerosis.
June 7, 2018
Find out more
Chronic Kidney Disease Market and Forecast Analysis to 2035
Read More
Chronic kidney disease is a progressive condition affecting over 10% of the world’s population, and is characterized by kidney damage and impaired kidney function.
April 11, 2018
Find out more
Chronic kidney disease
Read More
Chronic kidney disease (CKD) is a long-term condition characterized by declining kidney function

and kidney damage that affects over 10% of the world’s population.
December 13, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *